In a report released on May 10, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price target of $33.00. The company’s shares closed last Friday at $13.90.
Thompson CFA covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Argenx Se, and Dianthus Therapeutics. According to TipRanks, Thompson CFA has an average return of 13.8% and a 45.28% success rate on recommended stocks.
Viridian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $35.25, implying a 153.60% upside from current levels. In a report released on May 9, H.C. Wainwright also assigned a Buy rating to the stock with a $27.00 price target.
The company has a one-year high of $28.35 and a one-year low of $10.93. Currently, Viridian Therapeutics has an average volume of 922.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viridian Therapeutics (VRDN) Company Description:
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
Read More on VRDN:
- Viridian Therapeutics price target lowered to $31 from $36 at Oppenheimer
- Viridian Therapeutics downgraded to Neutral from Buy at Ladenburg
- Viridian Therapeutics price target lowered to $27 from $37 at H.C. Wainwright
- Viridian Therapeutics downgraded to Neutral from Buy at B. Riley
- Viridian Therapeutics reports Q1 EPS (79c), consensus ($1.10)
